Generative AI in Pharma Market
Published date: March 2024 • Report Code: 36896
Request Sample Order This Report
Generative AI in Pharma Market

Generative AI In Pharma Market Report By Application (Drug Discovery, Clinical Trial Research, Predictive Analytics, Disease Identification And Diagnosis, Personalized Medicine, Other Applications), By Technology (Machine Learning, Natural Language Processing (NLP), Deep Learning, Other Technologies), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2024-2033

  • 36896

  • March 2024

  • 155

  • Format PDF Format XLS Format PPT

    • ★★★★★
      ★★★★★
    • (13)

  • Technology and Media

This report was compiled by Vishwa Gaul Vishwa is an experienced market research and consulting professional with over 8 years of expertise in the ICT industry, contributing to over 700 reports across telecommunications, software, hardware, and digital solutions. Correspondence Team Lead- ICT Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page

  • Report Overview

    Global Generative AI in Pharma market size is expected to be worth around USD 2258.1 Mn by 2033 from USD 159.9 Mn in 2023, growing at a CAGR of 31.2% during the forecast period from 2024 to 2033.

    The surge in demand for the advanced technologies and rise in new medicines and pharmaceutical sectors are some of the main key driving factors for the generative AI in pharma.

    Generative AI in the pharma is defined as the new advanced technologies that uses machine learning algorithms to autonomously produce novel solutions and insights customized to pharmaceutical manufacturing and drug developments methods. It uses deep learning methods to analyse huge data sets, forecast molecular structures, enhance drug designs and simulate biological methods.

    Generative AI in Pharma Market By Size

    Generative AI makes the quick discovery of new discovery of new drug designs that facilitates tailored made medicines through accurate drug designs and fastens the enhancement of manufacturing techniques, like bio manufacturing and formulation developments.

    Moreover, it supports in drug repurposing by understanding present medications for new therapeutic uses. By integrating computational power with domain expertise, generative AI transforms drug discovery, development and production in the pharma sectors by leading to more efficient methods, decreasing expenses and enhances patient results.

    According to Master of code in February 2024, highlights that Adaptyv Bio has introduced a protein engineering foundry by using Gen AI, open source software and synthetic biology to create new medicines, enzymes and sustainable materials. Absci also unveils its uses of zero-shot AI in antibody designs by focusing to decrease the time to clinics for new medicament patients. Pharos iBio developed an AI-driven anticancer medication that addresses the FLT3 gene mutation.

    Moreover, Boston consulting group has also identified more than 130 potential use cases for gen AI in biopharma that ranges from patient identification by using health record data to automated medical text generation and digital sales agents. Furthermore, faster drug molecular design is resulting in a 25% reduction in production period.

    By using gen AI, it accelerates clinical developments by specifically in automating medical documents by minimizing writing time by 30%. DiffDock attained a 38% success rate in molecular docking predictions, exceptional both traditional methods (23%) and deep learning methods (20%). Recursion used AI to forecast targets for 36 billion compounds, making a scale of research in a week that would have taken 100,000 years with conventional approaches.

    Generative AI in pharma provides fast drug discovery through predictive modelling, molecular design and virtual screening, minimizing the time and cost. It improves customized medicines by personaling treatments to individual patients. Furthermore, it enhances the bioprocessing, formulation developments and drug repurposing, nurturing new innovations and enhancing healthcare solutions. The demand for the Generative AI in Pharma will increase due to its requirement in the pharmaceutical industries that will help in market expansion in the coming years.

    Key Takeaways

    • Market Value: The Global Generative AI in Pharma Market is projected to reach USD 2258.1 Million by 2033, experiencing substantial growth from its 2023 value, with a CAGR of 31.2% during the forecast period from 2024 to 2033.
    • Dominant Segments:
      • Application Analysis: Drug Discovery, Emerges as the dominant sub-segment, leveraging Generative AI's ability to accelerate the drug development process by identifying potential candidates quickly and cost-effectively.
      • Technology Analysis: Deep Learning, Leads the technology spectrum, offering profound capabilities in interpreting complex patterns within large datasets, particularly beneficial in drug discovery, protein structure prediction, and genomics.
    • Regional Analysis:
      • North America: Dominates with a 45.2% market share, driven by advanced research infrastructure and significant investments in healthcare AI.
      • Europe: Holds approximately 28% market share, supported by strong research infrastructure, public-private partnerships, and increasing healthcare AI investments.
    • Analyst Viewpoint: The market's growth is fueled by the urgent need to expedite drug discovery and development processes, enhance R&D efficiency, and deliver personalized healthcare solutions. Opportunities lie in further technological advancements, expanding application areas, and strengthening collaborations across the pharmaceutical ecosystem.
    • Market Key Players: Major players include Nvidia, Insilico Medicine Inc., Atomwise Inc., BenevolentAI Ltd., Numerate Inc., XtalPi Inc., Berg Health LLC, Conduent Incorporated, Fujitsu, OKRA.ai, and others.

    Driving Factors

    Accelerated Drug Discovery Drives Market Growth

    Generative AI is revolutionizing the pharmaceutical industry by significantly accelerating the drug discovery process. It achieves this by generating novel molecular structures and predicting drug interactions, thereby enabling the faster development of new medications. A notable collaboration in June 2023 involved the University of Toronto, Foxconn, and Insilico Medicine, focusing on the application of hybrid quantum-classical generative adversarial networks for small-molecule discovery.

    This advanced approach is anticipated to produce molecules with superior properties compared to those discovered through traditional methods. Such technological advancements are drawing more companies to invest in Generative AI solutions, underlining its potential to transform drug discovery. The ability to rapidly identify viable new compounds can drastically reduce the time to market for new drugs, making this technology a key driver in the growth of the Generative AI in the pharmaceutical market.

    Cost Savings and Efficiency Enhance Pharma Operations

    Merck's AI solution highlights the cost-saving potential of Generative AI in the pharmaceutical industry, promising up to 70% savings in time and costs for drug discovery. By automating labor-intensive processes and optimizing drug development, Generative AI brings about significant efficiency gains.

    These advancements not only streamline the drug development process but also enhance manufacturing efficiencies. The result is a substantial reduction in expenses and a boost in productivity for pharmaceutical companies. This economic advantage positions Generative AI as a crucial technological adoption for the industry, driving market growth through improved operational efficiency and cost-effectiveness in drug discovery and development.

    Personalized Medicine Advances Treatment Effectiveness

    Generative AI plays a pivotal role in the development of personalized medicine, enabling the creation of drugs that are tailored to the specific needs of patient groups. This bespoke approach to drug design significantly enhances treatment effectiveness while minimizing side effects, leading to better patient outcomes. Personalized medicine represents a shift towards more patient-centric treatment strategies, a movement that Generative AI is uniquely equipped to support.

    As the healthcare industry continues to emphasize individualized care, the demand for Generative AI technologies in drug development is expected to rise. The ability to develop treatments that are precisely aligned with individual patient profiles not only improves clinical outcomes but also drives the adoption of Generative AI solutions in the pharmaceutical sector, contributing to its growth.

    Restraining Factors

    Lack of Standardization Restrains Market Growth

    The absence of universally accepted standards significantly impedes the progress of Generative AI in the pharmaceutical sector. This gap in standardization means that outcomes of Generative AI applications in drug discovery are hard to compare and validate across different research initiatives. Without clear benchmarks or protocols, the industry struggles to develop models that are both accurate and reliable for concocting new chemical entities and testing scientific theories.

    This challenge not only affects the efficiency of research and development activities but also undermines the potential for collaborative innovation among scientists, regulatory bodies, and pharmaceutical companies. Ensuring the consistency of results and methodologies is crucial for fostering trust in AI-generated data and facilitating the broader acceptance and implementation of these technologies. Addressing this lack of standardization requires concerted efforts to establish comprehensive guidelines that can harmonize approaches to applying Generative AI in drug development.

    Regulatory and Compliance Challenges Restrains Market Growth

    Navigating the complex regulatory landscape of the pharmaceutical industry poses a formidable barrier to incorporating Generative AI technologies. Pharma companies must meticulously ensure that their use of AI in drug discovery and development complies with an array of stringent regulations. This involves adapting research methodologies and operational processes to meet industry standards, a task that demands significant time, resources, and expertise.

    The regulatory rigor is intended to safeguard public health and ensure the efficacy and safety of new drugs. However, it also slows the pace of innovation by imposing constraints on the exploration and implementation of advanced AI tools. The necessity to align AI applications with regulatory requirements not only prolongs the time to market for new treatments but also escalates costs. Overcoming these regulatory and compliance hurdles is essential for realizing the full potential of Generative AI in accelerating drug discovery and bringing revolutionary treatments to patients more efficiently.

    Application Analysis

    In the rapidly evolving Generative AI in Pharma Market, the application segment reveals insightful trends, particularly spotlighting Drug Discovery as the dominant sub-segment. This prominence is attributed to Generative AI's ability to significantly accelerate the drug development process, from initial discovery through to preclinical testing.

    AI's capacity to analyze vast datasets enables the identification of potential drug candidates at a speed and scale unattainable through traditional methods. This not only reduces the time frame for discovery but also potentially lowers costs, making it a pivotal area of investment for pharmaceutical companies aiming to enhance their R&D efficiency and productivity.

    Other segments, while not as dominant, play critical roles in the market's expansion. Clinical Trial Research benefits from Generative AI by optimizing trial designs and patient selection, thus enhancing the efficiency and success rates of clinical trials. Predictive Analytics utilizes AI to forecast disease trends and drug responses, which is crucial for both epidemic preparedness and personalized treatment plans. Disease Identification and Diagnosis, and Personalized Medicine are sectors where AI's ability to process and interpret complex biological data can lead to more accurate diagnoses and tailored treatment strategies, significantly impacting patient outcomes.

    Despite the clear dominance of Drug Discovery, the contribution of segments like Clinical Trial Research, Predictive Analytics, Disease Identification and Diagnosis, and Personalized Medicine cannot be understated. Each plays a unique role in supporting the overarching goal of faster, more efficient, and patient-centric drug development and healthcare solutions.

    Technology Analysis

    Within the technology spectrum of Generative AI in Pharma, Deep Learning stands out as the dominant sub-segment, primarily due to its profound capabilities in interpreting complex patterns within large datasets, a common challenge in pharmaceutical research.

    Deep Learning algorithms excel in identifying potential drug compounds, predicting their effectiveness, and highlighting possible side effects, thereby becoming an indispensable tool in the Drug Discovery process. Its application extends beyond mere discovery, facilitating advancements in areas like protein structure prediction and genomics, which are critical for understanding disease mechanisms and developing targeted therapies.

    Other technologies, including Machine Learning and Natural Language Processing (NLP), while not the frontrunners, are instrumental in broadening the application scope of Generative AI in Pharma. Machine Learning underpins many of the analytical tasks in drug discovery and development, offering predictive insights that guide decision-making. NLP, on the other hand, excels in extracting valuable information from unstructured data, such as scientific papers and clinical reports, thereby enhancing knowledge discovery and facilitating a deeper understanding of diseases and treatment outcomes.

    Deep Learning's preeminence does not diminish the significance of Machine Learning and NLP; rather, it underscores the complementary nature of these technologies. Machine Learning's predictive models and NLP's ability to decipher complex language and extract meaningful data are vital in streamlining research processes, enhancing data quality, and ultimately, speeding up the time-to-market for new drugs. Together, these technologies form a robust foundation for the Generative AI ecosystem in Pharma, each contributing uniquely to the sector's growth by improving accuracy, efficiency, and innovation in drug development and beyond.

    Generative AI in Pharma Market By Share

    Key Market Segments

    By Application

    • Drug Discovery
    • Clinical Trial Research
    • Predictive Analytics
    • Disease Identification and Diagnosis
    • Personalized Medicine
    • Other Applications

    By Technology

    • Machine Learning
    • Natural Language Processing (NLP)
    • Deep Learning
    • Other Technologies

    Growth Opportunities

    Supply Chain Optimization Offers Growth Opportunity

    The integration of Generative AI into the pharmaceutical supply chain and manufacturing processes marks a significant leap towards operational excellence. By leveraging AI to analyze vast arrays of data, including historical sales, market dynamics, and environmental factors, pharmaceutical companies can now predict demand with unprecedented accuracy.

    This not only ensures the uninterrupted supply of medicines but also significantly reduces waste, marrying efficiency with cost savings. Sanofi's adoption of AI for streamlining its manufacturing and supply chain operations serves as a prime example, showcasing how AI can drive substantial improvements in efficiency, resource management, and operational agility. The ability of AI to fine-tune the supply chain responds directly to the industry's need for more dynamic and responsive production systems, presenting a substantial opportunity for market growth.

    Collaborative Innovation Offers Growth Opportunity

    The burgeoning trend of collaboration among AI startups, pharmaceutical companies, and academic institutions is propelling the Generative AI market forward. These partnerships foster a rich environment for innovation, pooling together diverse expertise to tackle complex challenges in drug discovery and development.

    Collaborations, such as the one between Pharos Therapeutics and the University of Sydney, are pivotal in demonstrating the efficacy of AI-generated compounds, enhancing the drug development pipeline from discovery through to clinical trials. This ecosystem of collaborative innovation not only accelerates the pace of research and development but also opens up new avenues for market expansion, underscoring the critical role of partnerships in leveraging Generative AI to its fullest potential in the pharmaceutical industry.

    Trending Factors

    Cost-Effective Drug Development Are Trending Factors

    The drive towards more cost-effective drug development methodologies is shaping the adoption of Generative AI in the pharmaceutical industry. By automating and optimizing various stages of drug development, AI technologies offer significant reductions in the time and labor traditionally required, presenting opportunities for substantial cost savings and enhanced productivity.

    The key challenge lies in balancing the initial expenses of AI implementation against the efficiency and cost-reduction benefits it brings. As pharmaceutical companies refine their strategies to capitalize on these advantages, the trend towards leveraging AI for cost-effectiveness is becoming increasingly prominent, aligning with the industry's broader objectives of reducing drug development costs while meeting the demands of consumers and regulatory bodies.

    Regulatory Compliance and Standardization Are Trending Factors

    The push for improved regulatory compliance and standardization in the application of Generative AI within drug development is a critical trend driving the pharmaceutical market's growth and sustainability. The current lack of uniform standards complicates the comparison of research outcomes and the assurance of consistent results.

    Efforts to collaborate with researchers, regulatory bodies, and pharmaceutical partners aim to establish clear guidelines and elevate standards, tackling prevalent issues such as data privacy, security, and regulatory adherence. These initiatives are crucial for fostering trust in AI technologies, ensuring their ethical application, and facilitating their successful integration into the pharmaceutical industry. As the sector moves towards addressing these regulatory and standardization challenges, their resolution stands as a pivotal trend influencing the market's trajectory.

    Regional Analysis

    North America Dominates with 45.2% Market Share

    North America's leading position in the Generative AI in Pharma Market, holding a 45.2% share, is a reflection of several pivotal factors contributing to its dominance. This region's robust market share can be attributed to a strong ecosystem of pharmaceutical companies and tech giants, significant investments in AI and healthcare research, and a favorable regulatory environment that supports innovation. The presence of leading universities and research institutions further fuels the advancement of AI technologies, making North America a hub for innovation in Generative AI applications in pharmaceuticals.

    The dynamic nature of North America's pharmaceutical sector, characterized by high R&D spending, collaboration between academia and industry, and a swift adoption of technological advancements, underpins the region's supremacy. The regulatory bodies in this region, such as the FDA, are also progressive in adopting guidelines that facilitate the integration of AI in drug development, enhancing the region's attractiveness for AI-driven pharmaceutical innovations.

    Generative AI in Pharma Market

    Regional Market Shares

    • Europe: Europe holds a significant market share, accounting for approximately 28%, driven by its strong research infrastructure, public-private partnerships, and increasing investment in healthcare AI.
    • Asia Pacific: The Asia Pacific region, with a market share of 18%, is rapidly growing due to rising healthcare expenditures, digital transformation in the pharmaceutical sector, and supportive government policies towards AI and healthcare innovation.
    • Middle East & Africa: This region accounts for a smaller share of 5%, but it is gradually expanding with investments in healthcare infrastructure and a growing interest in adopting AI technologies.
    • Latin America: Latin America, holding a 3.8% market share, shows potential for growth with increasing awareness and adoption of AI in healthcare, despite facing challenges such as limited access to technology and funding.

    Key Regions and Countries

    • North America
      • The US
      • Canada
      • Mexico
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    In the Generative AI in Pharmaing Market, major players like Nvidia, Insilico Medicine Inc., and Atomwise Inc. play a crucial role in leveraging artificial intelligence (AI) to provide data-driven insights for informed decision-making in pharmaceutical research and development. These companies utilize cutting-edge technology and digital tools to analyze vast datasets and generate actionable insights, thereby addressing market volatility and enhancing strategic positioning.

    Insilico Medicine Inc., Atomwise Inc., and BenevolentAI Ltd. are at the forefront of AI-driven drug discovery, offering innovative solutions that expedite the identification of novel drug candidates and optimize molecular designs. By harnessing AI algorithms, these companies enable pharmaceutical companies to make informed decisions and accelerate the drug development process, ultimately improving patient outcomes.

    Nvidia, with its expertise in GPU-accelerated computing, provides the computational power necessary for training complex AI models in pharmaceutical research. Its technology plays a crucial role in enabling the widespread adoption of generative AI in pharmaing, facilitating the analysis of diverse datasets and the generation of AI-driven insights.

    Additionally, companies like Numerate Inc., XtalPi Inc., and Berg Health LLC contribute to the advancement of AI in pharmaceutical research, offering specialized solutions that leverage machine learning algorithms to uncover hidden patterns and relationships in biological data. By providing actionable insights, these companies empower pharmaceutical researchers to make informed decisions and drive innovation in drug discovery and development.

    Fujitsu, Conduent Incorporated, and OKRA.ai also play significant roles in the Generative AI in Pharmaing Market, offering comprehensive AI solutions that address various challenges faced by the pharmaceutical industry. Their strategic positioning and commitment to advancing AI technologies underscore their influence in shaping the future of pharmaceutical research and development.

    Market Key Players

    • Nvidia
    • Insilico Medicine Inc.
    • Atomwise Inc.
    • BenevolentAI Ltd.
    • Numerate Inc.
    • XtalPi Inc.
    • Berg Health LLC
    • Conduent Incorporated
    • Fujitsu
    • OKRA.ai
    • Other Key Players

    Recent Developments

    • On June 2023, Eli Lilly & Company and XtalPi Inc. launched an AI drug development alliance that could cost around $250 million in milestone and upfront payments. The partnership will use the robotics platform of XtalPi and its built-in AI to develop and distribute drug candidates from scratch to the unnamed goal.
    • On March 2023, Mitsui & Co Ltd. a Japanese company, announced a collaboration in 2023 with NVIDIA at Tokyo 1 to support the pharmaceutical industry in Japan with technology that uses the ability to generate AI models for the development of drugs.
    • On June 2023 University of Toronto, Foxconn, as well as Insilico Medicine, collaborated on a research project that seeks to study the application for hybrid quantum-classical, generative adversarial networks to aid in small-molecule discovery. The small molecules that are created using this technique are likely to have better properties than those produced by classical GANs.

    Report Scope

    Report Features Description
    Market Value (2023) USD 159.9 Mn
    Forecast Revenue (2033) USD 2258.1 Mn
    CAGR (2023-2033) 31.2%
    Base Year for Estimation 2023
    Historic Period 2017-2023
    Forecast Period 2023-2033
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Application (Drug Discovery, Clinical Trial Research, Predictive Analytics, Disease Identification and Diagnosis, Personalized Medicine, Other Applications), By Technology (Machine Learning, Natural Language Processing (NLP), Deep Learning, Other Technologies)
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Nvidia, Insilico Medicine Inc., Atomwise Inc., BenevolentAI Ltd., Numerate Inc., XtalPi Inc., Berg Health LLC, Conduent Incorporated, Fujitsu, OKRA.ai, Other Key Players
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

     

    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global Generative AI in Pharma Market Overview
      • 2.1. Generative AI in Pharma Market Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.3. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global Generative AI in Pharma Market Analysis, 2016-2021
      • 3.2. Global Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 3.3. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 3.3.1. Global Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 3.3.3. Software
        • 3.3.4. Services
      • 3.4. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 3.4.1. Global Generative AI in Pharma Market Analysis by Application: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 3.4.3. Drug Discovery
        • 3.4.4. Clinical Trials
        • 3.4.5. Personalized Medicines
        • 3.4.6. Disease Diagnosis
      • 3.5. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 3.5.1. Global Generative AI in Pharma Market Analysis by Technology: Introduction
        • 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 3.5.3. Natural Language Processing
        • 3.5.4. Context-Aware Processing
        • 3.5.5. Deep Learning
        • 3.5.6. Querying Method
        • 3.5.7. Other Technologies
      • 3.6. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 3.6.1. Global Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 3.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 3.6.3. Pharmaceutical Companies
        • 3.6.4. Contact Research Organizations
        • 3.6.5. Academic Research Institutes
        • 3.6.6. Government Organizations
      • 3.7. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 3.7.1. Global Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 3.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 3.7.3. On-premise
        • 3.7.4. Cloud-based
    • 4. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America Generative AI in Pharma Market Analysis, 2016-2021
      • 4.2. North America Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 4.3. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 4.3.1. North America Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 4.3.3. Software
        • 4.3.4. Services
      • 4.4. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 4.4.1. North America Generative AI in Pharma Market Analysis by Application: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 4.4.3. Drug Discovery
        • 4.4.4. Clinical Trials
        • 4.4.5. Personalized Medicines
        • 4.4.6. Disease Diagnosis
      • 4.5. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 4.5.1. North America Generative AI in Pharma Market Analysis by Technology: Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 4.5.3. Natural Language Processing
        • 4.5.4. Context-Aware Processing
        • 4.5.5. Deep Learning
        • 4.5.6. Querying Method
        • 4.5.7. Other Technologies
      • 4.6. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 4.6.1. North America Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 4.6.3. Pharmaceutical Companies
        • 4.6.4. Contact Research Organizations
        • 4.6.5. Academic Research Institutes
        • 4.6.6. Government Organizations
      • 4.7. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 4.7.1. North America Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 4.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 4.7.3. On-premise
        • 4.7.4. Cloud-based
      • 4.8. North America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.8.1. North America Generative AI in Pharma Market Analysis by Country : Introduction
        • 4.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.8.2.1. The US
          • 4.8.2.2. Canada
          • 4.8.2.3. Mexico
    • 5. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Western Europe Generative AI in Pharma Market Analysis, 2016-2021
      • 5.2. Western Europe Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 5.3. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 5.3.1. Western Europe Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 5.3.3. Software
        • 5.3.4. Services
      • 5.4. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 5.4.1. Western Europe Generative AI in Pharma Market Analysis by Application: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 5.4.3. Drug Discovery
        • 5.4.4. Clinical Trials
        • 5.4.5. Personalized Medicines
        • 5.4.6. Disease Diagnosis
      • 5.5. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 5.5.1. Western Europe Generative AI in Pharma Market Analysis by Technology: Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 5.5.3. Natural Language Processing
        • 5.5.4. Context-Aware Processing
        • 5.5.5. Deep Learning
        • 5.5.6. Querying Method
        • 5.5.7. Other Technologies
      • 5.6. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 5.6.1. Western Europe Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 5.6.3. Pharmaceutical Companies
        • 5.6.4. Contact Research Organizations
        • 5.6.5. Academic Research Institutes
        • 5.6.6. Government Organizations
      • 5.7. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 5.7.1. Western Europe Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 5.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 5.7.3. On-premise
        • 5.7.4. Cloud-based
      • 5.8. Western Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.8.1. Western Europe Generative AI in Pharma Market Analysis by Country : Introduction
        • 5.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.8.2.1. Germany
          • 5.8.2.2. France
          • 5.8.2.3. The UK
          • 5.8.2.4. Spain
          • 5.8.2.5. Italy
          • 5.8.2.6. Portugal
          • 5.8.2.7. Ireland
          • 5.8.2.8. Austria
          • 5.8.2.9. Switzerland
          • 5.8.2.10. Benelux
          • 5.8.2.11. Nordic
          • 5.8.2.12. Rest of Western Europe
    • 6. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Eastern Europe Generative AI in Pharma Market Analysis, 2016-2021
      • 6.2. Eastern Europe Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 6.3. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 6.3.1. Eastern Europe Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 6.3.3. Software
        • 6.3.4. Services
      • 6.4. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 6.4.1. Eastern Europe Generative AI in Pharma Market Analysis by Application: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 6.4.3. Drug Discovery
        • 6.4.4. Clinical Trials
        • 6.4.5. Personalized Medicines
        • 6.4.6. Disease Diagnosis
      • 6.5. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 6.5.1. Eastern Europe Generative AI in Pharma Market Analysis by Technology: Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 6.5.3. Natural Language Processing
        • 6.5.4. Context-Aware Processing
        • 6.5.5. Deep Learning
        • 6.5.6. Querying Method
        • 6.5.7. Other Technologies
      • 6.6. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 6.6.1. Eastern Europe Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 6.6.3. Pharmaceutical Companies
        • 6.6.4. Contact Research Organizations
        • 6.6.5. Academic Research Institutes
        • 6.6.6. Government Organizations
      • 6.7. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 6.7.1. Eastern Europe Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 6.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 6.7.3. On-premise
        • 6.7.4. Cloud-based
      • 6.8. Eastern Europe Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.8.1. Eastern Europe Generative AI in Pharma Market Analysis by Country : Introduction
        • 6.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.8.2.1. Russia
          • 6.8.2.2. Poland
          • 6.8.2.3. The Czech Republic
          • 6.8.2.4. Greece
          • 6.8.2.5. Rest of Eastern Europe
    • 7. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. APAC Generative AI in Pharma Market Analysis, 2016-2021
      • 7.2. APAC Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 7.3. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 7.3.1. APAC Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 7.3.3. Software
        • 7.3.4. Services
      • 7.4. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 7.4.1. APAC Generative AI in Pharma Market Analysis by Application: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 7.4.3. Drug Discovery
        • 7.4.4. Clinical Trials
        • 7.4.5. Personalized Medicines
        • 7.4.6. Disease Diagnosis
      • 7.5. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 7.5.1. APAC Generative AI in Pharma Market Analysis by Technology: Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 7.5.3. Natural Language Processing
        • 7.5.4. Context-Aware Processing
        • 7.5.5. Deep Learning
        • 7.5.6. Querying Method
        • 7.5.7. Other Technologies
      • 7.6. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 7.6.1. APAC Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 7.6.3. Pharmaceutical Companies
        • 7.6.4. Contact Research Organizations
        • 7.6.5. Academic Research Institutes
        • 7.6.6. Government Organizations
      • 7.7. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 7.7.1. APAC Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 7.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 7.7.3. On-premise
        • 7.7.4. Cloud-based
      • 7.8. APAC Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.8.1. APAC Generative AI in Pharma Market Analysis by Country : Introduction
        • 7.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.8.2.1. China
          • 7.8.2.2. Japan
          • 7.8.2.3. South Korea
          • 7.8.2.4. India
          • 7.8.2.5. Australia & New Zeland
          • 7.8.2.6. Indonesia
          • 7.8.2.7. Malaysia
          • 7.8.2.8. Philippines
          • 7.8.2.9. Singapore
          • 7.8.2.10. Thailand
          • 7.8.2.11. Vietnam
          • 7.8.2.12. Rest of APAC
    • 8. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Latin America Generative AI in Pharma Market Analysis, 2016-2021
      • 8.2. Latin America Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 8.3. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 8.3.1. Latin America Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 8.3.3. Software
        • 8.3.4. Services
      • 8.4. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 8.4.1. Latin America Generative AI in Pharma Market Analysis by Application: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 8.4.3. Drug Discovery
        • 8.4.4. Clinical Trials
        • 8.4.5. Personalized Medicines
        • 8.4.6. Disease Diagnosis
      • 8.5. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 8.5.1. Latin America Generative AI in Pharma Market Analysis by Technology: Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 8.5.3. Natural Language Processing
        • 8.5.4. Context-Aware Processing
        • 8.5.5. Deep Learning
        • 8.5.6. Querying Method
        • 8.5.7. Other Technologies
      • 8.6. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 8.6.1. Latin America Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 8.6.3. Pharmaceutical Companies
        • 8.6.4. Contact Research Organizations
        • 8.6.5. Academic Research Institutes
        • 8.6.6. Government Organizations
      • 8.7. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 8.7.1. Latin America Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 8.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 8.7.3. On-premise
        • 8.7.4. Cloud-based
      • 8.8. Latin America Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.8.1. Latin America Generative AI in Pharma Market Analysis by Country : Introduction
        • 8.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.8.2.1. Brazil
          • 8.8.2.2. Colombia
          • 8.8.2.3. Chile
          • 8.8.2.4. Argentina
          • 8.8.2.5. Costa Rica
          • 8.8.2.6. Rest of Latin America
    • 9. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, 2016-2032
      • 9.1. Middle East & Africa Generative AI in Pharma Market Analysis, 2016-2021
      • 9.2. Middle East & Africa Generative AI in Pharma Market Opportunity and Forecast, 2023-2032
      • 9.3. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Product Type, 2016-2032
        • 9.3.1. Middle East & Africa Generative AI in Pharma Market Analysis by Product Type: Introduction
        • 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product Type, 2016-2032
        • 9.3.3. Software
        • 9.3.4. Services
      • 9.4. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Application, 2016-2032
        • 9.4.1. Middle East & Africa Generative AI in Pharma Market Analysis by Application: Introduction
        • 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
        • 9.4.3. Drug Discovery
        • 9.4.4. Clinical Trials
        • 9.4.5. Personalized Medicines
        • 9.4.6. Disease Diagnosis
      • 9.5. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Technology, 2016-2032
        • 9.5.1. Middle East & Africa Generative AI in Pharma Market Analysis by Technology: Introduction
        • 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Technology, 2016-2032
        • 9.5.3. Natural Language Processing
        • 9.5.4. Context-Aware Processing
        • 9.5.5. Deep Learning
        • 9.5.6. Querying Method
        • 9.5.7. Other Technologies
      • 9.6. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 9.6.1. Middle East & Africa Generative AI in Pharma Market Analysis by End-Users: Introduction
        • 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 9.6.3. Pharmaceutical Companies
        • 9.6.4. Contact Research Organizations
        • 9.6.5. Academic Research Institutes
        • 9.6.6. Government Organizations
      • 9.7. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Deployment, 2016-2032
        • 9.7.1. Middle East & Africa Generative AI in Pharma Market Analysis by Deployment: Introduction
        • 9.7.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Deployment, 2016-2032
        • 9.7.3. On-premise
        • 9.7.4. Cloud-based
      • 9.8. Middle East & Africa Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 9.8.1. Middle East & Africa Generative AI in Pharma Market Analysis by Country : Introduction
        • 9.8.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 9.8.2.1. Algeria
          • 9.8.2.2. Egypt
          • 9.8.2.3. Israel
          • 9.8.2.4. Kuwait
          • 9.8.2.5. Nigeria
          • 9.8.2.6. Saudi Arabia
          • 9.8.2.7. South Africa
          • 9.8.2.8. Turkey
          • 9.8.2.9. The UAE
          • 9.8.2.10. Rest of MEA
    • 10. Global Generative AI in Pharma Market Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 10.1. Global Generative AI in Pharma Market Analysis by Region : Introduction
      • 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 10.2.1. North America
        • 10.2.2. Western Europe
        • 10.2.3. Eastern Europe
        • 10.2.4. APAC
        • 10.2.5. Latin America
        • 10.2.6. Middle East & Africa
    • 11. Global Generative AI in Pharma Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 11.1. Market Share Analysis
      • 11.2. Company Profiles
      • 11.3. Insilico Medicine Inc.
        • 11.3.1. Company Overview
        • 11.3.2. Financial Highlights
        • 11.3.3. Product Portfolio
        • 11.3.4. SWOT Analysis
        • 11.3.5. Key Strategies and Developments
      • 11.4. Atomwise Inc.
        • 11.4.1. Company Overview
        • 11.4.2. Financial Highlights
        • 11.4.3. Product Portfolio
        • 11.4.4. SWOT Analysis
        • 11.4.5. Key Strategies and Developments
      • 11.5. BenevolentAI Ltd.
        • 11.5.1. Company Overview
        • 11.5.2. Financial Highlights
        • 11.5.3. Product Portfolio
        • 11.5.4. SWOT Analysis
        • 11.5.5. Key Strategies and Developments
      • 11.6. Numerate Inc.
        • 11.6.1. Company Overview
        • 11.6.2. Financial Highlights
        • 11.6.3. Product Portfolio
        • 11.6.4. SWOT Analysis
        • 11.6.5. Key Strategies and Developments
      • 11.7. XtalPi Inc.
        • 11.7.1. Company Overview
        • 11.7.2. Financial Highlights
        • 11.7.3. Product Portfolio
        • 11.7.4. SWOT Analysis
        • 11.7.5. Key Strategies and Developments
      • 11.9. Other Key Players
        • 11.9.1. Company Overview
        • 11.9.2. Financial Highlights
        • 11.9.3. Product Portfolio
        • 11.9.4. SWOT Analysis
        • 11.9.5. Key Strategies and Developments
    • 12. Assumptions and Acronyms
    • 13. Research Methodology
    • 14. Contact

    List of Figures

    • Figure 1: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Type in 2022
    • Figure 2: Global Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 3: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 4: Global Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 5: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 6: Global Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 7: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 8: Global Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 9: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 10: Global Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 11: Global Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Region in 2022
    • Figure 12: Global Generative AI in Pharma Market Attractiveness Analysis by Region, 2016-2032
    • Figure 13: Global Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 14: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Region (2016-2032)
    • Figure 15: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 16: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 17: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 18: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 19: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 20: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
    • Figure 21: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 22: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 23: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 24: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 25: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 26: Global Generative AI in Pharma Market Share Comparison by Region (2016-2032)
    • Figure 27: Global Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 28: Global Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 29: Global Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 30: Global Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 31: Global Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 32: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 33: North America Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 34: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 35: North America Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 36: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 37: North America Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 38: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 39: North America Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 40: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 41: North America Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 42: North America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 43: North America Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 44: North America Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 45: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 46: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 47: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 48: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 49: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 50: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 51: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 52: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 53: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 54: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 55: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 56: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 57: North America Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 58: North America Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 59: North America Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 60: North America Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 61: North America Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 62: North America Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 63: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 64: Western Europe Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 65: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 66: Western Europe Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 67: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 68: Western Europe Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 69: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 70: Western Europe Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 71: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 72: Western Europe Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 73: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 74: Western Europe Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 75: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 76: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 77: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 78: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 79: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 80: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 81: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 82: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 83: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 84: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 85: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 86: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 87: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 88: Western Europe Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 89: Western Europe Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 90: Western Europe Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 91: Western Europe Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 92: Western Europe Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 93: Western Europe Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 94: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 95: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 96: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 97: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 98: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 99: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 100: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 101: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 102: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 103: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 104: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 105: Eastern Europe Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 106: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 107: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 108: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 109: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 110: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 111: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 112: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 113: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 114: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 115: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 116: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 117: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 118: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 119: Eastern Europe Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 120: Eastern Europe Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 121: Eastern Europe Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 122: Eastern Europe Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 123: Eastern Europe Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 124: Eastern Europe Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 125: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 126: APAC Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 127: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 128: APAC Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 129: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 130: APAC Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 131: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 132: APAC Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 133: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 134: APAC Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 135: APAC Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 136: APAC Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 137: APAC Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 138: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 139: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 140: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 141: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 142: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 143: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 144: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 145: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 146: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 147: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 148: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 149: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 150: APAC Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 151: APAC Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 152: APAC Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 153: APAC Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 154: APAC Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 155: APAC Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 156: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 157: Latin America Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 158: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 159: Latin America Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 160: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 161: Latin America Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 162: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 163: Latin America Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 164: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 165: Latin America Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 166: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 167: Latin America Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 168: Latin America Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 169: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 170: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 171: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 172: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 173: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 174: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 175: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 176: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 177: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 178: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 179: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 180: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 181: Latin America Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 182: Latin America Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 183: Latin America Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 184: Latin America Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 185: Latin America Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 186: Latin America Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Figure 187: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Product Typein 2022
    • Figure 188: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by Product Type, 2016-2032
    • Figure 189: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Applicationin 2022
    • Figure 190: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by Application, 2016-2032
    • Figure 191: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Technologyin 2022
    • Figure 192: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by Technology, 2016-2032
    • Figure 193: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by End-Usersin 2022
    • Figure 194: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by End-Users, 2016-2032
    • Figure 195: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Deploymentin 2022
    • Figure 196: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by Deployment, 2016-2032
    • Figure 197: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Market Share by Country in 2022
    • Figure 198: Middle East & Africa Generative AI in Pharma Market Attractiveness Analysis by Country, 2016-2032
    • Figure 199: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
    • Figure 200: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
    • Figure 201: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
    • Figure 202: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
    • Figure 203: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
    • Figure 204: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
    • Figure 205: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
    • Figure 206: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
    • Figure 207: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
    • Figure 208: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
    • Figure 209: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
    • Figure 210: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
    • Figure 211: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
    • Figure 212: Middle East & Africa Generative AI in Pharma Market Share Comparison by Country (2016-2032)
    • Figure 213: Middle East & Africa Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
    • Figure 214: Middle East & Africa Generative AI in Pharma Market Share Comparison by Application (2016-2032)
    • Figure 215: Middle East & Africa Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
    • Figure 216: Middle East & Africa Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
    • Figure 217: Middle East & Africa Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)

    List of Tables

      • Table 1: Global Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 2: Global Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 3: Global Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 4: Global Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 5: Global Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 6: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 7: Global Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 8: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 9: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 10: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 11: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 12: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 13: Global Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 14: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 15: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 16: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 17: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 18: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 19: Global Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 20: Global Generative AI in Pharma Market Share Comparison by Region (2016-2032)
      • Table 21: Global Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 22: Global Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 23: Global Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 24: Global Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 25: Global Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 26: North America Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 27: North America Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 28: North America Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 29: North America Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 30: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 31: North America Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 32: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 33: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 34: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 35: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 36: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 37: North America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 38: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 39: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 40: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 41: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 42: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 43: North America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 44: North America Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 45: North America Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 46: North America Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 47: North America Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 48: North America Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 49: North America Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 50: Western Europe Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 51: Western Europe Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 52: Western Europe Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 53: Western Europe Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 54: Western Europe Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 55: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 56: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 57: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 58: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 59: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 60: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 61: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 62: Western Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 63: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 64: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 65: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 66: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 67: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 68: Western Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 69: Western Europe Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 70: Western Europe Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 71: Western Europe Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 72: Western Europe Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 73: Western Europe Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 74: Western Europe Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 75: Eastern Europe Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 76: Eastern Europe Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 77: Eastern Europe Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 78: Eastern Europe Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 79: Eastern Europe Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 80: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 81: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 82: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 83: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 84: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 85: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 86: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 87: Eastern Europe Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 88: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 89: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 90: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 91: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 92: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 93: Eastern Europe Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 94: Eastern Europe Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 95: Eastern Europe Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 96: Eastern Europe Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 97: Eastern Europe Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 98: Eastern Europe Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 99: Eastern Europe Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 100: APAC Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 101: APAC Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 102: APAC Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 103: APAC Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 104: APAC Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 105: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 106: APAC Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 107: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 108: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 109: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 110: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 111: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 112: APAC Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 113: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 114: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 115: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 116: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 117: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 118: APAC Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 119: APAC Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 120: APAC Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 121: APAC Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 122: APAC Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 123: APAC Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 124: APAC Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 125: Latin America Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 126: Latin America Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 127: Latin America Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 128: Latin America Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 129: Latin America Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 130: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 131: Latin America Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 132: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 133: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 134: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 135: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 136: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 137: Latin America Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 138: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 139: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 140: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 141: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 142: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 143: Latin America Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 144: Latin America Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 145: Latin America Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 146: Latin America Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 147: Latin America Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 148: Latin America Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 149: Latin America Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
      • Table 150: Middle East & Africa Generative AI in Pharma Market Comparison by Product Type (2016-2032)
      • Table 151: Middle East & Africa Generative AI in Pharma Market Comparison by Application (2016-2032)
      • Table 152: Middle East & Africa Generative AI in Pharma Market Comparison by Technology (2016-2032)
      • Table 153: Middle East & Africa Generative AI in Pharma Market Comparison by End-Users (2016-2032)
      • Table 154: Middle East & Africa Generative AI in Pharma Market Comparison by Deployment (2016-2032)
      • Table 155: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 156: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) (2016-2032)
      • Table 157: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 158: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Product Type (2016-2032)
      • Table 159: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Application (2016-2032)
      • Table 160: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Technology (2016-2032)
      • Table 161: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 162: Middle East & Africa Generative AI in Pharma Market Revenue (US$ Mn) Comparison by Deployment (2016-2032)
      • Table 163: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 164: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Product Type (2016-2032)
      • Table 165: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
      • Table 166: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Technology (2016-2032)
      • Table 167: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 168: Middle East & Africa Generative AI in Pharma Market Y-o-Y Growth Rate Comparison by Deployment (2016-2032)
      • Table 169: Middle East & Africa Generative AI in Pharma Market Share Comparison by Country (2016-2032)
      • Table 170: Middle East & Africa Generative AI in Pharma Market Share Comparison by Product Type (2016-2032)
      • Table 171: Middle East & Africa Generative AI in Pharma Market Share Comparison by Application (2016-2032)
      • Table 172: Middle East & Africa Generative AI in Pharma Market Share Comparison by Technology (2016-2032)
      • Table 173: Middle East & Africa Generative AI in Pharma Market Share Comparison by End-Users (2016-2032)
      • Table 174: Middle East & Africa Generative AI in Pharma Market Share Comparison by Deployment (2016-2032)
    • Insilico Medicine Inc.
    • Atomwise Inc.
    • BenevolentAI Ltd.
    • Numerate Inc.
    • XtalPi Inc.
    • Berg Health LLC.
    • Other Key Players
✖
Request a Sample Report
We'll get back to you as quickly as possible

Wnat a quick look at the report?
Request Sample
Do you have a query?
Speak with analyst
Need personalized modifications?
Customize Report

Our Clients

  • Our Clients
    Our Clients

View Our Licence Options

Order This Report
Report Methodology Research Methodology
LOOKING FOR A PERSONALIZED REPORT?
Our team specializes in tailoring reports to your specific needs, and the best part? It's absolutely free. Whether you require standalone sections, country-level analysis, or discounts tailored for start-ups and universities, we've got you covered.
Request for Customization

MARKET RESEARCH REPORTS

MarketResearch.biz (Powered by Prudour Pvt. Ltd.) delivers customized research solutions by actuating its broad spectrum of research methodologies, databases, and resources, and this is further strengthened by our global experience in syndicated and customized industry projects.

Our tailor-made research services include quick market scans, country reports, in-depth market analysis, competition monitoring, consumer research and satisfaction studies, supplier research, growth planning, and quite a lot more.

SHORT NAVIGATION

CONTACT US